Combined Treatment of Non‐Small‐Cell Lung Cancer Using Shenyi Capsule and Platinum‐Based Chemotherapy: A Meta‐Analysis and Systematic Review

Abstract

Background.The efficacy and safety of combined treatment of non-small-cell lung cancer (NSCLC) using Shenyi capsules and platinum-based chemotherapy were comprehensively evaluated. Methods. A computer-based search was used to identify reports on clinical randomized controlled trials (RCTs) on this combined treatment for NSCLC from the PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, China Biomedical (CBM), and Wanfang Data electronic databases. The databases were searched from their start to February 2020. The quality of the included studies was evaluated and then crosschecked by two independent evaluators. A meta-analysis was conducted using RevMan5.3. Results. A total of 27 RCTs involving 2,663 patients were included in the meta-analysis, including 1,380 and 1,283 patients in the treatment and control groups, respectively. The results of the meta-analysis showed that, compared to platinum-based chemotherapy alone, the 1-year survival rate (relative risk (RR) = 1.27, 95% confidence interval (CI) [1.10, 1.47], P < 0.01 ), 2-year survival rate (RR = 1.35, 95% CI [1.10, 1.65], P < 0.01 ), objective tumour remission rate (RR = 1.52, 95% CI [1.35, 1.71], P < 0.01 ), and body CD4+/CD8+ ratio (standardized mean difference (SMD) = 0.12, 95% CI [0.07, 0.17], P < 0.01 ) were increased for the combined treatment of NSCLC using Shenyi capsules and platinum-based chemotherapy; moreover, quality of life was also improved (RR = 2.09, 95%CI [1.75, 2.50], P < 0.01 ) and it reduced leukocyte toxicity (RR = 0.49, 95%CI [0.39, 0.63], P < 0.01 ), haemoglobin toxicity (RR = 0.48, 95% CI [0.28, 0.81], P < 0.01 ), platelet toxicity (RR = 0.44, 95% CI [0.28, 0.70], P < 0.01 ), vomiting reaction (RR = 0.60, 95% CI [0.45, 0.78], P < 0.01 ), and serum vascular endothelial growth factor level (SMD = −63.67, 95% CI [−67.59, −59.75], P < 0.01 ). Conclusions. The treatment of NSCLC using Shenyi capsules together with routine platinum-based chemotherapy could enhance short- and long-term efficacy, improve patient quality of life, alleviate toxicity and side-effects of platinum-based chemotherapeutic drugs, boost body immune function, and inhibit tumour neovascularisation. These findings require further validation in large-sample, high-quality RCTs.

Ginsenoside Rg3 Attenuates Early Hepatic Injury via Inhibiting PPARγ- and Ang II-Related Inflammation and Fibrosis in Type II Diabetic Mice

“…Of which the principal component is Rg 3 , Shenyi Capsule produced by our company (Jilin Yatai Pharmaceutical Co., Ltd.) has been applied as an adjuvant to conventional cancer therapies in China. 9,10 In addition to its anti-cancer activity, the cardiovascular protective effects of Rg 3 have also been shown by our group and others in a variety of animal disease models, including myocardial infarction, 11 hypertension, 12 and atherosclerosis. 13 Along this line, we found that Rg 3 improves hypertensive nephropathy in rats and mice with hypertension.…”

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC

“…Adverse reactions were classified according to the toxicity classification standards of the WHO and divided into grades 0–IV. Grade II–IV toxicities were considered adverse reactions [ 19 ]. Secondary outcome indices of efficacy were leukocyte and platelet toxicities, as well as vomiting in the digestive tract.…”

The Effect of Shenyi Capsule on Non-Small-Cell Lung Cancer Combined with Chemotherapy from the Yin-Yang Perspective

“…e first meta-analysis of chemotherapy and optimal supportive treatment for advanced NSCLC published in the Journal of Clinical Oncology (2008) has confirmed that supportive treatment combined with chemotherapy can improve the survival rate of advanced NSCLC [26,27] and has a significant effect in reducing toxic side effects [28] and chemoresistance [29] of chemotherapy. Obviously, chemotherapy has a direct cytotoxic effect on NSCLC [30][31][32], while Shenyi capsule synergically increases the efficacy of chemotherapy by reducing toxicity, increasing sensitization, enhancing immunity, etc.…”

“…Because there is no single mechanism that can explain the nature of toxic side effects and chemoresistance, the combination therapy based on different mechanisms cannot really get rid of them. Aiming at the abovementioned defects of chemotherapy, the combination of Shenyi capsule mainly improves severe acute vomiting above Grade II [27] and effectively improves hemocytotoxicity and platelet inhibition caused by chemotherapy [27]. Due to the "vascular inhibition effect" of Shenyi capsule [38], the "vascular network" that tumors depend on for survival is blocked, and the rapid proliferation of tumor during the intermittent period of chemotherapeutics is also blocked, which effectively consolidates the phased curative effect achieved by chemotherapy.…”

“…erefore, the body immunity itself is retained to the maximum extent, and the tolerance of the body to chemical drugs is improved as well. Consequently, in the treatment of NSCLC, the combination of Shenyi capsule and chemical drugs has a better clinical advantage than chemotherapy alone [27].…”